A molecularly targeted theranostic probe for ovarian cancer

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Overexpression of the human epidermal growth factor receptor (HER) family is linked to ovarian cancer progression.
• Ovarian cancer has a high mortality rate due to a lack of effective diagnostic and therapeutic strategies.
• HER2 receptor expression offers a potential target for nanotherapies in drug-resistant ovarian cancer.

Purpose of the Study:

• To develop and evaluate a novel gold nanoshell-based nanocomplex for targeting, dual modal imaging, and photothermal therapy of HER2-overexpressing, drug-resistant ovarian cancer cells (OVCAR3) in vitro.
• To assess the specificity of the nanocomplex for HER2-overexpressing cells.
• To investigate the efficacy of photothermal therapy using the nanocomplex and near-infrared laser irradiation.

Main Methods:

• Engineered gold nanoshell-based nanocomplexes capable of fluorescence optical imaging and magnetic resonance imaging.
• Conjugated nanocomplexes with anti-HER2 antibodies for targeted delivery.
• Utilized immunofluorescence staining and magnetic resonance imaging to confirm specific binding to OVCAR3 cells.
• Irradiated targeted nanocomplexes with near-infrared laser for photothermal ablation of cancer cells.

Main Results:

• Nanocomplex-anti-HER2 conjugates demonstrated specific binding to HER2-overexpressing OVCAR3 cells compared to control MDA-MB-231 cells.
• Photothermal ablation using near-infrared laser irradiation selectively destroyed OVCAR3 cancer cells.
• Both near-infrared light therapy and the nanocomplexes alone were found to be non-cytotoxic in vitro.

Conclusions:

• This study presents the first successful integration of dual modal bioimaging with photothermal cancer therapy for ovarian cancer treatment.
• The developed nanocomplexes show significant promise for image-guided photothermal therapy of ovarian cancer.
• These nanocomplexes are potentially applicable to other HER2-overexpressing cancers.